{"protocolSection":{"identificationModule":{"nctId":"NCT06480552","orgStudyIdInfo":{"id":"TV56278-ONC-10203"},"organization":{"fullName":"Teva Branded Pharmaceutical Products R&D, Inc.","class":"INDUSTRY"},"briefTitle":"An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors","officialTitle":"A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-07-24","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2029-05-26","type":"ESTIMATED"},"completionDateStruct":{"date":"2031-02-25","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-10","studyFirstSubmitQcDate":"2024-06-24","studyFirstPostDateStruct":{"date":"2024-06-28","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-06-24","lastUpdatePostDateStruct":{"date":"2024-06-28","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Teva Branded Pharmaceutical Products R&D, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The primary objectives of this trial are to:\n\n* Characterize the safety and tolerability of TEV-56278\n* Determine the Recommended Phase 2 Dose (RP2D)\n* Evaluate antitumor activity of TEV-56278\n* Determine the safety and tolerability of TEV-56278 in combination with pembrolizumab\n* Determine a RP2D of TEV-56278 in combination with pembrolizumab\n\nThe secondary objectives of this trial are to:\n\n* Characterize the serum pharmacokinetics of TEV-56278\n* Evaluate the antitumor activity of TEV-56278\n* Determine the safety and tolerability of TEV-56278\n* Evaluate other measures of antitumor activity of TEV-56278\n* Evaluate anti-tumor activity\n\nParticipants will be treated up to 12 months with a follow-up period of up to 12 months after last infusion. The total duration of the trial will be up to 25 months for individual participants."},"conditionsModule":{"conditions":["Advanced Solid Tumors"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"SEQUENTIAL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":240,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"TEV-56278 Monotherapy; Dose Escalation","type":"EXPERIMENTAL","interventionNames":["Drug: TEV-56278"]},{"label":"TEV-56278 Monotherapy; Dose Expansion","type":"EXPERIMENTAL","interventionNames":["Drug: TEV-56278"]},{"label":"TEV-56278 in Combination with Pembrolizumab; Dose Escalation","type":"EXPERIMENTAL","interventionNames":["Drug: TEV-56278","Drug: Pembrolizumab"]}],"interventions":[{"type":"DRUG","name":"TEV-56278","description":"Administered intravenously","armGroupLabels":["TEV-56278 Monotherapy; Dose Escalation","TEV-56278 Monotherapy; Dose Expansion","TEV-56278 in Combination with Pembrolizumab; Dose Escalation"]},{"type":"DRUG","name":"Pembrolizumab","description":"Administered intravenously","armGroupLabels":["TEV-56278 in Combination with Pembrolizumab; Dose Escalation"],"otherNames":["KEYTRUDA®"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Incidence of AEs with CTCAE Grade≥3 in the escalation phase","description":"CTCAE: Common Terminology Criteria for Adverse Events","timeFrame":"Up to 15 months after 1st infusion in the escalation phase"},{"measure":"Incidence of SAEs in the escalation phase","timeFrame":"Up to 15 months after 1st infusion in the escalation phase"},{"measure":"Incidence of AEs meeting protocol-defined DLT criteria in the escalation phase","description":"DLT: dose-limiting toxicity","timeFrame":"Up to 28 days after 1st infusion in the escalation phase"},{"measure":"Incidence of dose modifications due to AEs in the escalation phase","timeFrame":"Up to 12 months after 1st infusion in the escalation phase"},{"measure":"Incidence of AEs leading to discontinuation in the escalation phase","timeFrame":"Up to 12 months after 1st infusion in the escalation phase"},{"measure":"Recommended Phase 2 dose as monotherapy","timeFrame":"Up to 24 months after 1st infusion"},{"measure":"Objective Response Rate (ORR) based on RECIST criteria in the expansion phase","description":"RECIST: Response Evaluation Criteria in Solid Tumors.","timeFrame":"Up to 24 months after the 1st dose in the expansion phase"},{"measure":"Duration of Response (DOR) in the expansion phase","timeFrame":"Up to 24 months after the 1st dose in the expansion phase"},{"measure":"Recommended Phase 2 dose in combination with Pembrolizumab","timeFrame":"Up to 24 months after 1st dose"},{"measure":"Incidence of AEs with CTCAE Grade≥3 in the combination phase","timeFrame":"Up to 15 months after 1st infusion in the combination phase"},{"measure":"Incidence of SAEs in the combination phase","timeFrame":"Up to 15 months after 1st infusion in the combination phase"},{"measure":"Incidence of AEs meeting protocol-defined DLT criteria in the combination phase","timeFrame":"Up to 28 days after 1st infusion in the combination phase"},{"measure":"Incidence of dose modifications due to AEs in the combination phase","timeFrame":"Up to 12 months after 1st infusion in the combination phase"},{"measure":"Incidence of AEs leading to discontinuation in the combination phase","timeFrame":"Up to 12 months after 1st infusion in the combination phase"}],"secondaryOutcomes":[{"measure":"AUC0-last","description":"Area under the serum concentration-time curve from time 0 to last measurable drug concentration","timeFrame":"Predose up to Day 8"},{"measure":"Cmax","description":"Maximum observed concentration","timeFrame":"Predose up to Day 8"},{"measure":"tmax","description":"Time to maximum observed drug concentration","timeFrame":"Predose up to Day 8"},{"measure":"Objective Response Rate (ORR) based on RECIST criteria in the escalation phase","timeFrame":"Up to 24 months after 1st infusion in the escalation phase"},{"measure":"Incidence of AEs with CTCAE Grade≥3 in the expansion phase","timeFrame":"Up to 24 months after 1st infusion in the expansion phase"},{"measure":"Incidence of SAEs in the expansion phase","timeFrame":"Up to 15 months after 1st infusion in the expansion phase"},{"measure":"Incidence of dose modifications due to AEs in the expansion phase","timeFrame":"Up to 12 months after 1st infusion in the expansion phase"},{"measure":"Incidence of AEs leading to discontinuation in the expansion phase","timeFrame":"Up to 12 months after 1st infusion in the expansion phase"},{"measure":"Disease Control Rate (DCR) according to RECIST (v1.1) criteria","timeFrame":"Up to 24 months after 1st infusion"},{"measure":"Time to Respond (TTR) according to RECIST (v1.1) criteria","timeFrame":"Up to 24 months after 1st infusion"},{"measure":"Objective Response Rate (ORR) based on RECIST criteria in the combination phase","timeFrame":"Up to 24 months after 1st infusion in the combination phase"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have an established histological diagnosis of selected solid tumor and must have received and progressed on established standard therapies or have been intolerant to such therapy or have been considered by the Investigator as ineligible for approved standard therapy\n* Have a life expectancy≥12 weeks at the time of the screening\n* Women of childbearing potential must agree to use highly effective methods of contraception for the course of the trial through 120 days after the last dose of trial medication\n* Males who are sexually active with women of childbearing potential must agree to use condoms and refrain from donating sperm for the course of the trial through 120 days after the last dose of trial medication\n\nNOTE- Additional criteria apply, please contact the investigator for more information\n\nExclusion Criteria:\n\n* Has a history of systemic treatment therapy for cancer (including chemotherapy, immunotherapy, radiotherapy, or other investigational drug) or surgery within 4 weeks prior to baseline\n* Is currently receiving or has received hematopoietic colony-stimulating growth factors within 2 weeks before screening or transfusion support 4 weeks prior to screening\n* Has a diagnosis of immunodeficiency\n* Has active known autoimmune disease.\n* Has a history of or known active brain metastases and/or carcinomatous meningitis and/or leptomeningeal metastasis\n* Has active or uncontrolled serious infections requiring systemic therapy within 14 days prior to baseline\n* Has a history of clinically significant cardiovascular or cerebrovascular disease in previous 6 months prior to screening\n* Has evidence of clinically significant interstitial lung disease or active, noninfectious pneumonitis\n* Has a seizure disorder requiring therapy (such as steroids or antiepileptics)\n\nNOTE- Additional criteria apply, please contact the investigator for more information","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Teva U.S. Medical Information","role":"CONTACT","phone":"1-888-483-8279","email":"USMedInfo@tevapharm.com"}],"overallOfficials":[{"name":"Teva Medical Expert, MD","affiliation":"Teva Branded Pharmaceutical Products R&D, Inc.","role":"STUDY_DIRECTOR"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Qualified researchers may request access to patient level data and related study documents including the study protocol and the statistical analysis plan. Requests will be reviewed for scientific merit, product approval status, and conflicts of interest. Patient level data will be de-identified and study documents will be redacted to protect the privacy of trial participants and to protect commercially confidential information. Please visit www.clinicalstudydatarequest.com to make your request."}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"meshes":[{"id":"D000009369","term":"Neoplasms"}]},"interventionBrowseModule":{"meshes":[{"id":"C000582435","term":"Pembrolizumab"}],"ancestors":[{"id":"D000074322","term":"Antineoplastic Agents, Immunological"},{"id":"D000000970","term":"Antineoplastic Agents"},{"id":"D000082082","term":"Immune Checkpoint Inhibitors"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"}],"browseLeaves":[{"id":"M349416","name":"Pembrolizumab","asFound":"Breast","relevance":"HIGH"},{"id":"M1346","name":"Antineoplastic Agents, Immunological","relevance":"LOW"},{"id":"M2342","name":"Immune Checkpoint Inhibitors","relevance":"LOW"}],"browseBranches":[{"abbrev":"ANeo","name":"Antineoplastic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}